Trial Profile
Pancreatic Enzyme Replacement Therapy in patients after Major Upper Gastro-Intestinal Operations (PERTUGI) - A Randomized Controlled Trial to Assess Weight Change, Quality of Life, and Faecal Elastase in patients receiving enzyme supplementation with Creon (Trademark)
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 31 Jan 2018
Price :
$35
*
At a glance
- Drugs Pancrelipase (Primary)
- Indications Exocrine pancreatic insufficiency
- Focus Therapeutic Use
- Acronyms PERTUGI
- 31 Jan 2018 Planned End Date changed from 31 Oct 2017 to 31 Jan 2019.
- 22 Apr 2013 New trial record